RxDoctor Payments Data

Christine Marcotte, DO

Family Medicine · Dyer, INNPI 1104879477

Payments from drug & device makers

$3,806in general payments, 2019–2025

Across 215 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$681
  • Novo Nordisk$582
  • AbbVie$506
  • Johnson & Johnson$274
  • Novartis$233
  • Pfizer$233
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,806 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$381,088
Medicare patients
549
Services billed
8,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$64,034
OzempicSemaglutide37$47,321
RexultiBrexpiprazole11$18,717
ArexvyRsvpref3 Antigen/As01e/Pf48$14,874
ShingrixVaricella-Zoster Ge/As01b/Pf50$11,096
SynthroidLevothyroxine Sodium145$8,861
SymbicortBudesonide/Formoterol Fumarate11$6,394
Levothyroxine Sodium455$4,696
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen195$3,742
Rosuvastatin Calcium390$3,678
Metoprolol Succinate229$2,942
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine15$2,812
Alprazolam289$2,651
Losartan Potassium353$2,628
Atorvastatin Calcium322$2,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$64,03451 claims
Novo NordiskOzempic$582$47,32137 claims
GSKArexvy, Shingrix$58$25,97098 claims
Otsuka America Pharmaceutical, Inc.Rexulti$201$18,71711 claims
AbbVieSynthroid$506$8,861145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →